Ubs Group Ag Lixte Biotechnology Holdings, Inc. Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.51 - $1.89 $635 - $2,356	1,247 Added 13.16%	10,722 $8,000
Q4 2022 Feb 08, 2023	BUY	$0.48 - $6.0 $1,105 - $13,818	2,303 Added 32.11%	9,475 $4,000
Q3 2022 Nov 10, 2022	BUY	$0.12 - $5.9 $328 - $16,136	2,735 Added 61.64%	7,172 $4,000
Q2 2022 Aug 10, 2022	SELL	$0.12 - $0.35 $345 - $1,008	-2,882 Reduced 39.38%	4,437 $3,000
Q1 2022 May 16, 2022	SELL	$0.16 - $0.35 $30 - $65	-188 Reduced 2.5%	7,319 $9,000
Q4 2021 Feb 14, 2022	BUY	$0.21 - $0.57 $728 - $1,976	3,468 Added 85.86%	7,507 $9,000
Q3 2021 Nov 15, 2021	BUY	$0.52 - $0.85 $1,109 - $1,813	2,134 Added 112.02%	4,039 $8,000
Q2 2021 Aug 13, 2021	BUY	$0.46 - $0.89 $876 - $1,695	1,905 New	1,905 $6,000
Q1 2021 May 12, 2021	SELL	$0.8 - $1.2 $1,346 - $2,019	-1,683 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$0.72 - $58.7 $1,211 - $98,792	1,683 New	1,683 $5,000

Ticker LIXT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,646,600
Market Cap $33M
Description
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agent...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.